CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS
- Written by PR Newswire
- FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy
- Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic
- Phase 1A clinical trial to initiate patient enrolment in 2024
- Phase 1A clinical trial will enroll patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours
SYDNEY, Oct....
